» Articles » PMID: 36949957

Mediated Clonal Hematopoiesis Confers Increased Risk for Incident Atherosclerotic Disease

Abstract

Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across multiple beds, with increased risk among individuals with CHIP driven by mutation in DNA Damage Repair (DDR) genes such as and . To model the effects of DDR-induced CHIP on atherosclerosis, we used a competitive bone marrow transplantation strategy, and generated atherosclerosis-prone -/- chimeric mice carrying 20% p53-deficient hematopoietic cells. The chimeric mice were analyzed 13-weeks post-grafting and showed increased aortic plaque size and accumulation of macrophages within the plaque, driven by increased proliferation of p53-deficient plaque macrophages. In summary, our findings highlight the role of CHIP as a broad driver of atherosclerosis across the entire arterial system beyond the coronary arteries, and provide genetic and experimental support for a direct causal contribution of TP53-mutant CHIP to atherosclerosis.

Citing Articles

Clonal haematopoiesis of indeterminate potential: an emerging risk factor for type 2 diabetes and related complications.

Zuriaga M, Fuster J Diabetologia. 2025; .

PMID: 40064675 DOI: 10.1007/s00125-025-06393-8.


The Role of Somatic Mutations in Ischemic Stroke: CHIP's Impact on Vascular Health.

Kinzhebay A, Salybekov A Neurol Int. 2025; 17(2).

PMID: 39997650 PMC: 11858376. DOI: 10.3390/neurolint17020019.


Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms and inflammation.

Tan H, Jiang H, Wang S Ann Hematol. 2025; .

PMID: 39988580 DOI: 10.1007/s00277-025-06244-x.


Clonal hematopoiesis of indeterminate potential, health indicators, and risk of cardiovascular diseases among patients with diabetes: a prospective cohort study.

Sun Y, Yu Y, Cai L, Yu B, Xiao W, Tan X Cardiovasc Diabetol. 2025; 24(1):72.

PMID: 39948662 PMC: 11827465. DOI: 10.1186/s12933-025-02626-7.


Bone Marrow Niche in Cardiometabolic Disease: Mechanisms and Therapeutic Potential.

Kohutek Z, Caslin H, Fehrenbach D, Heimlich J, Brown J, Madhur M Circ Res. 2025; 136(3):325-353.

PMID: 39883790 PMC: 11790260. DOI: 10.1161/CIRCRESAHA.124.323778.


References
1.
Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

2.
Conte M, Bradbury A, Kolh P, White J, Dick F, Fitridge R . Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019; 69(6S):3S-125S.e40. PMC: 8365864. DOI: 10.1016/j.jvs.2019.02.016. View

3.
Min K, Polizio A, Kour A, Thel M, Walsh K . Experimental -Mediated Clonal Hematopoiesis Promotes Inflammation and Accelerates Heart Failure. J Am Heart Assoc. 2022; 11(19):e026154. PMC: 9673733. DOI: 10.1161/JAHA.122.026154. View

4.
Song P, Rudan D, Zhu Y, Fowkes F, Rahimi K, Fowkes F . Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019; 7(8):e1020-e1030. DOI: 10.1016/S2214-109X(19)30255-4. View

5.
Bondar T, Medzhitov R . p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell. 2010; 6(4):309-322. PMC: 2872065. DOI: 10.1016/j.stem.2010.03.002. View